H.C. Wainwright Reaffirms Their Buy Rating on Legend Biotech (LEGN)

Tip Ranks
2025.11.14 11:37
portai
I'm PortAI, I can summarize articles.

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Legend Biotech (LEGN) with a price target of $60.00. Kapoor has an average return of -0.1% and a 41.76% success rate. Morgan Stanley’s Terence Flynn also issued a Buy rating, while another analyst reiterated a Hold rating on the same day.

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Legend Biotech today and set a price target of $60.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, Kapoor is an analyst with an average return of -0.1% and a 41.76% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Halozyme, Ionis Pharmaceuticals, and Neurogene.

In addition to H.C. Wainwright, Legend Biotech also received a Buy from Morgan Stanley’s Terence Flynn in a report issued yesterday. However, on the same day, TR | OpenAI – 4o reiterated a Hold rating on Legend Biotech (NASDAQ: LEGN).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer